News Home

Wednesday, June 21, 2023 10:12 AM | InvestorsObserver Analysts

Mentioned in this article

Overall market sentiment has been high on Esperion Therapeutics Inc (ESPR) stock lately. ESPR receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Esperion Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ESPR!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.

Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.

InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What’s Happening With ESPR Stock Today?

Esperion Therapeutics Inc (ESPR) stock is trading at $1.39 as of 10:05 AM on Wednesday, Jun 21, a drop of -$0.14, or -9.26% from the previous closing price of $1.53. The stock has traded between $1.38 and $1.54 so far today. Volume today is below average. So far 571,165 shares have traded compared to average volume of 2,636,011 shares.

More About Esperion Therapeutics Inc

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.

Click Here to get the full Stock Report for Esperion Therapeutics Inc stock.

You May Also Like